Abdallah MA, Harrad S (2009) Personal exposure to HBCDs and its degradation products via ingestion of indoor dust. Environ Int 35(6):870–876. https://doi.org/10.1016/j.envint.2009.03.002

Article  PubMed  CAS  Google Scholar 

Abdallah MAE, Harrad S, Ibarra C et al (2008) Hexabromocyclododecanes in indoor dust from Canada, the United Kingdom, and the United States. Environ Sci Technol 42(2):459–464. https://doi.org/10.1021/es702378t

Article  CAS  Google Scholar 

Alaee M, Arias P, Sjodin A, Bergman A (2003) An overview of commercially used brominated flame retardants, their applications, their use patterns in different countries/regions and possible modes of release. Environ Int 29(6):683–689

Article  PubMed  CAS  Google Scholar 

Andersen ME (2003) Toxicokinetic modeling and its applications in chemical risk assessment. Toxicol Lett 138(1–2):9–27

Article  PubMed  CAS  Google Scholar 

Australian-Government (2012) Hexabromocyclododecane. Online ISBN: 978-1-74241-716-5

Barrett JR (2013) POPs vs. fat: persistent organic pollutant toxicity targets and is modulated by adipose tissue. Environ Health Perspect 121(2):a61. https://doi.org/10.1289/ehp.121-a61

Article  PubMed  PubMed Central  Google Scholar 

Birnbaum LS, Staskal DF (2004) Brominated flame retardants: cause for concern? Environ Health Perspect 112(1):9–17

Article  PubMed  PubMed Central  CAS  Google Scholar 

Brown RP, Delp MD, Lindstedt SL, Rhomberg L, Belisles R (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13(4):407–484

Article  PubMed  CAS  Google Scholar 

Chengelis RP (1997) A 28-day repeated dose oral toxicity study of hbcd in rats. In: WIL Research Laboratories A, OH (ed)

Covaci A, Gerecke AC, Law RJ et al (2006) Hexabromocyclododecanes (HBCDs) in the environment and humans: a review. Environ Sci Technol 40(12):3679–3688. https://doi.org/10.1021/es0602492

Article  PubMed  CAS  Google Scholar 

Dobrev ID, Reddy MB, Plotzke KP et al (2003) Closed-chamber inhalation pharmacokinetic studies with hexamethyldisiloxane in the rat. Inhal Toxicol 15(6):589–617

Article  PubMed  CAS  Google Scholar 

Dobrev ID, Nong A, Liao KH, Reddy MB, Plotzke KP, Andersen ME (2008) Assessing kinetic determinants for metabolism and oral uptake of octamethylcyclotetrasiloxane (D4) from inhalation chamber studies. Inhal Toxicol 20(4):361–373. https://doi.org/10.1080/08958370801903743

Article  PubMed  CAS  Google Scholar 

Easterling MR, Evans MV, Kenyon EM (2000) Comparative analysis of software for physiological based pharmacokinetic modeling: Simulation, optimization and sensibility analysis. Toxicol Mech Methods 10(3):203–229

Article  CAS  Google Scholar 

EBFRIP (2009) An evaluation of hexabromocyclododecane (HBCD) for Persistent Organic Pollutant (POP) properties and the potential for adverse effects in the environment In: Arnot JA, McCarty L, Armitage J, Toose-Reaid L, Wania F, Cousins I (eds). European Brominated Flame Retardant Industry Panel (EBFRIP), p 214

ECHA (2009a) Data on manufacture, import, export, uses and releases of HBCDD as well as information on potential alternatives to its use, p 108

ECHA (2009b) Member state committee support document for identification of hexabromocyclododecane and all major diastereoisomers as a substance of very high concern

Eckardstein Av (2020) LDL contributes to reverse cholesterol transport. Circ Res 127(6):793–795. https://doi.org/10.1161/CIRCRESAHA.120.317721

Article  CAS  Google Scholar 

EFSA (2011a) Scientific opinion on hexabromocyclododecanes (HBCDDs) in food (panel on contaminants in the food chain). EFSA J 9(7):2296. https://doi.org/10.2903/j.efsa.2011.2296

Article  CAS  Google Scholar 

EFSA (2011b) Scientific opinion on polybrominated diphenyl ethers (PBDEs) in food (panel on contaminants in the food chain). EFSA J 9(5):2156. https://doi.org/10.2903/j.efsa.2011.2156

Article  CAS  Google Scholar 

EFSA (2021) Update of the risk assessment of hexabromocyclododecanes (HBCDDs) in food. EFSA, p 130

Google Scholar 

Emond C, Birnbaum LS, DeVito M (2004) Physiologically based pharmacokinetic model for developmental exposures to TCDD in the rat. Toxicol Sci 80(1):115–133

Article  PubMed  CAS  Google Scholar 

Emond C, DeVito MJ, Birnbaum LS (2021) A PBPK model describing the pharmacokinetics of γ-HBCD exposure in mice. Toxicol Appl Pharmacol 428:115678. https://doi.org/10.1016/j.taap.2021.115678

Article  PubMed  PubMed Central  CAS  Google Scholar 

Eriksson P, Fischer C, Wallin M, Jakobsson E, Fredriksson A (2006) Impaired behaviour, learning and memory, in adult mice neonatally exposed to hexabromocyclododecane (HBCDD). Environ Toxicol Pharmacol 21(3):317–322. https://doi.org/10.1016/j.etap.2005.10.001

Article  PubMed  CAS  Google Scholar 

Erratico C, Zheng X, van den Eede N, Tomy G, Covaci A (2016) Stereoselective metabolism of alpha-, beta-, and gamma-hexabromocyclododecanes (HBCDs) by human liver microsomes and CYP3A4. Environ Sci Technol 50(15):8263–8273. https://doi.org/10.1021/acs.est.6b01059

Article  PubMed  CAS  Google Scholar 

Fetzner S, Lingens F (1994) Bacterial dehalogenases: biochemistry, genetics, and biotechnological applications. Microbiol Rev 58(4):641–685. https://doi.org/10.1128/mr.58.4.641-685.1994

Article  PubMed  PubMed Central  CAS  Google Scholar 

GastroPlus (2018) GastroPlus Simulation software for drug discovery and development (version 9.6). Simulation Plus, p 748

Genskow KR, Bradner JM, Hossain MM, Richardson JR, Caudle WM (2015) Selective damage to dopaminergic transporters following exposure to the brominated flame retardant. HBCDD Neurotoxicol Teratol 52(Pt B):162–169. https://doi.org/10.1016/j.ntt.2015.06.003

Article  PubMed  CAS  Google Scholar 

Geyer HJ, Schramm KW, Darnerud PO et al (2004) Terminal elimination half-lives of the brominated flame retardants TBBPA, HBCD, and lower brominated PBDEs in humans. Paper presented at the Dioxin 2004, Berlin Germany

Hakk H (2016) Comparative metabolism studies of hexabromocyclododecane (HBCD) diastereomers in male rats following a single oral dose. Environ Sci Technol 50(1):89–96

Article  PubMed  CAS  Google Scholar 

Heeb NV, Schweizer WB, Mattrel P et al (2007) Solid-state conformations and absolute configurations of (+) and (−) alpha-, beta-, and gamma-hexabromocyclododecanes (HBCDs). Chemosphere 68(5):940–950. https://doi.org/10.1016/j.chemosphere.2007.01.032

Article  PubMed  CAS  Google Scholar 

Hjelmborg PS, Andreassen TK, Bonefeld-Jorgensen EC (2008) Cellular uptake of lipoproteins and persistent organic compounds—an update and new data. Environ Res 108(2):192–198. https://doi.org/10.1016/j.envres.2008.07.019

Article  PubMed  CAS  Google Scholar 

Ibhazehiebo K, Iwasaki T, Shimokawa N, Koibuchi N (2011) 1,2,5,6,9,10-αHexabromocyclododecane (HBCD) impairs thyroid hormone-induced dendrite arborization of Purkinje cells and suppresses thyroid hormone receptor-mediated transcription. Cerebellum 10(1):22–31. https://doi.org/10.1007/s12311-010-0218-1

Article  PubMed  CAS  Google Scholar 

Jackson E, Shoemaker R, Larian N, Cassis L (2017) Adipose tissue as a site of toxin accumulation. Compr Physiol 7(4):1085–1135. https://doi.org/10.1002/cphy.c160038

Article  PubMed  PubMed Central  Google Scholar 

Kabir ER, Rahman MS, Rahman I (2015) A review on endocrine disruptors and their possible impacts on human health. Environ Toxicol Pharmacol 40(1):241–258

Article  PubMed  CAS  Google Scholar 

Kajiwara N, Sueoka M, Ohiwa T, Takigami H (2009) Determination of flame-retardant hexabromocyclododecane diastereomers in textiles. Chemosphere 74(11):1485–1489. https://doi.org/10.1016/j.chemosphere.2008.11.046

Article  PubMed  CAS  Google Scholar 

KEMI (2008) Risk assessment hexabromocyclododecane (CAS-no. 25637-99-4; EINECS-No. 247-148-4). Final version, p 507

Koch C, Schmidt-Kotters T, Rupp R, Sures B (2015) Review of hexabromocyclododecane (HBCD) with a focus on legislation and recent publications concerning toxicokinetics and -dynamics. Environ Pollut 199:26–34. https://doi.org/10.1016/j.envpol.2015.01.011

Article  PubMed  CAS